低风险甲状腺癌主动监测的超声影像标准与方案:国际共识指南综述
本文综述韩国甲状腺放射学会(KSThR)关于低风险甲状腺微小乳头状癌主动监测(AS)的标准化超声影像指南,涵盖AS启动与随访阶段的肿瘤评估推荐,并将其关键特征与国际主要指南比较,指出影像方法与随访策略的异同,旨在支持AS的更广泛实施并改善患者结局。
要点
- AS是低风险甲状腺微小乳头状癌(PTMC)除立即手术外的替代管理选项。
- AS期间定期超声监测肿瘤生长、提示大体甲状腺外侵犯的新超声特征及淋巴结转移。
- 影像评估在决定继续AS或转为手术干预中起关键作用。
核心结论
- KSThR指南为低风险PTMC主动监测的启动与随访阶段提供标准化超声影像的实用推荐,影像评估对指导继续AS或手术决策至关重要。
研究设计与样本
- 综述:介绍KSThR关于低风险PTMC主动监测标准化超声影像的指南,并与主要国际指南的关键特征进行比较。
临床应用与阅片要点
- AS启动前需基于个体与肿瘤特异性特征及超声表现仔细选择患者。
- AS期间定期超声监测肿瘤生长、提示大体甲状腺外侵犯的新超声特征及淋巴结转移。
- 依据影像评估结果决定继续AS或转为手术干预。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Given the indolent nature and favorable outcomes of papillary thyroid microcarcinoma (PTMC), active surveillance (AS) has been adopted as an alternative management option to immediate surgery. However, the meticulous selection of patients based on individual and tumor-specific characteristics, as well as ultrasound (US) findings, is crucial in AS. Regular US monitoring is performed during AS to detect indicators of tumor progression, such as growth, the emergence of new US features suggestive of gross extrathyroidal extension, and lymph node metastasis. Thus, imaging-based evaluations play a pivotal role in guiding the decision to continue AS or proceed with surgical intervention. This review introduces the Korean Society of Thyroid Radiology (KSThR) guideline for the standardized US imaging of patients with low-risk PTMC under AS, which provide practical recommendations for tumor assessment during the initiation and follow-up phases of AS. This review compared the key features of the KSThR guideline with those of major international guidelines and identified the similarities and differences in imaging methodologies and follow-up strategies. The primary objective of this review is to support the broader implementation of AS and improve outcomes for patients with low-risk PTMC by emphasizing imaging protocols.
引用
- Lee JY, Na DG. Ultrasound Imaging Criteria and Protocols for Active Surveillance of Low-Risk Thyroid Cancer: A Review of International Consensus Guidelines. Endocrinol Metab (Seoul). 2025. PMID: 40140733. doi:10.3803/EnM.2024.2319
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。